Evidence map›Paper›PMID 40847358›Full record

ArticleOrphanet journal of rare diseases2025

Psychometric evaluation of novel hyperphagia questionnaires in a real-world setting for patients with a rare MC4R pathway disease.

Jeremy Pomeroy, Usha G Mallya, Min Yang, Caroline Huber, Alexandra Greatsinger, Ella Hagopian, Andrea M Haqq

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jeremy PomeroyMarshfield Clinic Research Institute, Marshfield, WI, USA.
Usha G MallyaRhythm Pharmaceuticals, Inc., Boston, MA, USA.
Min YangAnalysis Group, Inc., Boston, MA, USA. Min.Yang@analysisgroup.com.ORCID 0000-0002-4864-6658
Caroline HuberRhythm Pharmaceuticals, Inc., Boston, MA, USA.
Alexandra GreatsingerAnalysis Group, Inc., Boston, MA, USA.
Ella HagopianAnalysis Group, Inc., Boston, MA, USA.
Andrea M HaqqDivision of Pediatric Endocrinology, University of Alberta, Edmonton, AB, Canada.

Funding

Rhythm Pharmaceuticals, Inc Rhythm Pharmaceuticals, Inc
6 · The paper itself

Abstract

backgroundThere are no validated measures to assess hyperphagia associated with rare MC4R pathway diseases, such as Bardet-Biedl Syndrome (BBS). Symptoms of Hyperphagia© (SoH) and Impacts of Hyperphagia© (IoH) are novel questionnaires designed to assess signs and symptoms of hyperphagia and their impacts on patients and caregivers. We evaluated the psychometric performance of the caregiver-versions of the SoH: Caregiver (Observer-reported) and IoH: Caregiver (Observer-reported and Self-reported subscales).

resultsReliability and validity were evaluated using data from a multi-country cross-sectional survey of adult caregivers of patients with BBS experiencing hyperphagia and obesity. Other instruments included were Impact of Weight on Quality of Life (IWQOL)-Kids (Parent Proxy), PROMIS Scale Global Health of Caregiver, Revised Impact on Family Scale (RIOFS), and Work Productivity and Activity Impairment. 242 eligible caregivers completed the survey. Exploratory factor analysis identified 1 factor per subscale. Strong internal consistency was observed for IoH: Caregiver (Observer) (Cronbach's a = 0.66) and IoH: Caregiver (Self) (a = 0.72) and moderate for SoH: Caregiver (Observer) (a = 0.40). Moderate-to-strong correlations were observed with school days missed and all domains of IWQOL-Kids except Physical Comfort (range = 0.315-0.573, p's < 0.001). Known-groups indicated significantly worse SoH: Caregiver subscores for patients using appetite suppressants or implementing more weight management approaches (6-10 vs. ≤5 or > 10). Caregivers reporting greater strain on RIOFS items and worse mental health had worse IoH subscores.

conclusionsThe SoH: Caregiver and IoH: Caregiver demonstrated preliminary validity, reliability, and consistency in a real-world setting. Research is underway to further validate these measures for use in clinical trials for BBS and other MC4R pathway-related diseases associated with obesity.

Indexed as

HyperphagiaPsychometricsReceptor, Melanocortin, Type 4AdultCaregiversCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuality of LifeSurveys and QuestionnairesYoung AdultMC4R protein, humanReceptor, Melanocortin, Type 4Bardet-Biedl syndromeHyperphagiaMC4R pathway diseasesObesityPatient-reported outcomePsychometric evaluationValidity

Identifiers

PMID40847358
PMCPMC12372303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.